Helius Medical Technologies Inc (NAS:HSDT)
$ 0.5622 -0.0365 (-6.1%) Market Cap: 2.01 Mil Enterprise Value: -4.38 Mil PE Ratio: 0 PB Ratio: 0.28 GF Score: 54/100
Back to the Transcripts List

Q1 2024 Helius Medical Technologies Inc Earnings Call Transcript

May 13, 2024 / 08:30PM GMT
Release Date Price: $1.69 (+3.52%)

Key Points

Positve
  • Helius Medical Technologies Inc (HSDT) secured CMS Medicare HCPCS codes for PoNS device, enhancing reimbursement opportunities.
  • The company announced a $6.4 million financing, extending its cash runway into 2025, supporting ongoing projects.
  • Helius Medical Technologies Inc (HSDT) is making significant progress in its stroke authorization pursuit in the U.S., adding new clinical sites and aligning with FDA on development plans.
  • Partnership with Lovell Government Services to make PoNS available to VA and DoD, expanding access to federal healthcare systems.
  • Positive preliminary Medicare payment determinations for PoNS devices, with expectations for favorable final determinations to boost revenue.
Negative
  • Despite advancements, the final Medicare payment rates for PoNS devices are still under negotiation, with uncertainty about the outcomes.
  • Net loss reported for Q1 2024 was $2.5 million, indicating ongoing financial challenges despite reduced operating loss.
  • Revenues remain low at $135,000 for Q1 2024, reflecting the niche market and high price points of PoNS devices.
  • The dependency on future CMS reimbursement approvals to significantly boost revenue introduces risk if approvals are delayed or lower than expected.
  • Helius Medical Technologies Inc (HSDT) faces challenges in expanding its physical therapist network for PoNS therapy, critical for patient access and treatment efficacy.
Operator

Good day and thank you for standing by. Welcome to the Helius Medical Technologies first quarter 2024 earnings conference call. (Operator Instructions) Please be advised today's conference is being recorded. I would like to hand the conference over to your speaker today, Michelle Bilski, with In-Site Communications, please go ahead.

Michelle Bilski
In-Site Communications Inc - Investor Relations

Thank you, Kevin. Welcome to the first quarter 2024 earnings conference call for Helios Medical Technologies. This is Michelle Bilski of In-sight Communications, Investor Relations for Helios. With me on today's call are Dane Andreeff, Helios Medical's President, and Chief Executive Officer; and Jeff Mathiesen, Chief Financial Officer.

At this time, all participants have been placed in a listen-only mode. Please note that this call is being recorded and access to the webcast can be obtained through the investor section of the Helios website at www.heliosmedical.com.

Before we begin

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.